Kures Overview

  • Founded
  • 2017
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Kures General Information

Description

Developer of therapeutics intended for mood disorders. The company targets the important intersection between pain and opioid use disorder and its product is under evaluation for the treatment of subsets of depression through a unique mechanism of action, providing medical practitioners with a potentially safer and more widely available alternative for both pain management and opioid maintenance therapy.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Parent Company
Primary Office
  • 9 Fairlawn Avenue
  • Dobbs Ferry, NY 10522
  • United States
+1 (929) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kures Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 09-Jul-2020 00.000 Completed Generating Revenue
1. Early Stage VC (Series A1) 28-Aug-2019 00.000 00.000 00.000 Completed Stealth
To view Kures’s complete valuation and funding history, request access »

Kures Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00
Series A-2 10,800,000 $0.000100 8% $0.42 $0.42 1x $0.42 0%
To view Kures’s complete cap table history, request access »

Kures Executive Team (2)

Name Title Board Seat Contact Info
Srinivas Rao Ph.D Chief Executive Officer
Andrew Kruegel Ph.D Co-Founder, President & CSO
To view Kures’s complete executive team members history, request access »